Dimerix (ASX: DXB) is pleased to announce the appointment of a Medical Advisory Board (MAB) to help guide the Company’s DMX-200 clinical program.
The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and progresses its DMX-200 programs. The MAB will have no formal governance role.
Associate Professor David Packham (MD, MB, BS (Hons), FRCP, FRACP) will lead the MAB in the position of Chair, where he will be joined by:
The Medical Advisory Board will provide clinical and strategic input into the Company’s lead program, DMX-200 in Chronic Kidney Disease and will provide guidance to the Company as it shapes and progresses its DMX-200 programs. The MAB will have no formal governance role.
Associate Professor David Packham (MD, MB, BS (Hons), FRCP, FRACP) will lead the MAB in the position of Chair, where he will be joined by:
- Professor David Power, MD, MB, BS, PhD, MRCP(UK), FRACP
- Daniel Cattran, MD, FRCP (C)
- Alessia Fornoni, MD, PhD, FASN
- Jonathan Hogan, MD
Further background on each of the Advisory Board members can be found in the appendix following.
Kathy Harrison, group CEO commented, “We are delighted to have attracted such a respected group of nephrologists to join this inaugural Medical Advisory Board, particularly as the DMX-200 program in Chronic Kidney Disease moves closer to phase 2b trials.
“The formation of this Board will help drive forward the clear clinical potential of our DMX-200 program. The MAB members’ insights and guidance will prove invaluable as we design and advance our program.”
The Medical Advisory Board is compensated for its time through a combination cash and equity based remuneration, with the total number of shares to be issued of 2,743,000 (pre consolidation) and a package of options to be issued to the approximate value of $10,000 the precise number and exercise price to be determined.
Kathy Harrison, group CEO commented, “We are delighted to have attracted such a respected group of nephrologists to join this inaugural Medical Advisory Board, particularly as the DMX-200 program in Chronic Kidney Disease moves closer to phase 2b trials.
“The formation of this Board will help drive forward the clear clinical potential of our DMX-200 program. The MAB members’ insights and guidance will prove invaluable as we design and advance our program.”
The Medical Advisory Board is compensated for its time through a combination cash and equity based remuneration, with the total number of shares to be issued of 2,743,000 (pre consolidation) and a package of options to be issued to the approximate value of $10,000 the precise number and exercise price to be determined.
